<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04986839</url>
  </required_header>
  <id_info>
    <org_study_id>B01039</org_study_id>
    <nct_id>NCT04986839</nct_id>
  </id_info>
  <brief_title>PAIR (Paracetamol and Ibuprofen Research) Pilot Trial</brief_title>
  <acronym>PAIR</acronym>
  <official_title>PAIR (Paracetamol and Ibuprofen Research) Study: A Randomised Controlled Trial Comparing IV Paracetamol With IV Ibuprofen in the Management of Haemodynamically Significant Patent Ductus Arteriosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Manchester University NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Presence of Patent Ductus Arteriosus is detrimental to an infant born prematurely. The&#xD;
      primary objective is to study the efficacy of Paracetamol (proposed new treatment) in&#xD;
      treating haemodynamic significant Patent Ductus Arteriosus (hsPDA) in comparison to Ibuprofen&#xD;
      (current standard treatment) in preterm infants. Outcome of such treatment will check on the&#xD;
      conversion of hsPDA to non-hsPDA. All preterm infants (born at &lt;32 weeks gestational age or&#xD;
      birth weight &lt; 1500 grams) with haemodynamically significant patent ductus arteriosus (hsPDA)&#xD;
      who are ≤ 28 days old will be included over 2 years. Sample size 32. Secondary outcomes of&#xD;
      this study will compare&#xD;
&#xD;
      1) BPD (broncho-pulmonary dysplasia) free survival at 36 weeks post menstrual age (PMA), 2)&#xD;
      incidence of complications of prematurity in each group and 3) to record any evidence of&#xD;
      adverse effects with Paracetamol or Ibuprofen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patent Ductus Arteriosus (PDA) is present in 40-60 percent of preterm infants. A persistent&#xD;
      PDA with a large left to right ductal shunt may be 'haemodynamically significant' (hsPDA)&#xD;
      resulting in pulmonary hyper-perfusion and systemic hypo-perfusion. The association of a PDA&#xD;
      with an increased incidence of pulmonary haemorrhage, bronchopulmonary dysplasia and&#xD;
      prolonged need for ventilatory support is ascribed to pulmonary hyper-perfusion, whereas&#xD;
      necrotising enterocolitis, renal failure, cerebral haemorrhage, and periventricular&#xD;
      leukomalacia are consequences of systemic hypo-perfusion. In the United Kingdom, Ibuprofen (a&#xD;
      non-steroidal anti-inflammatory drug, NSAID) is used to treat hsPDA in preterm babies.&#xD;
      Paracetamol has come up recently as a promising alternative with fewer side effects and has&#xD;
      been used in the management of PDA with promising results. However, the current available&#xD;
      body of evidence is considered to be of moderate to low quality and hence its effectiveness&#xD;
      and safety profile is not fully established in this patient population. The primary objective&#xD;
      is to study the efficacy of IV paracetamol in treating hsPDA in comparison to IV ibuprofen in&#xD;
      preterm infants born at less than 32 weeks' gestation OR less than 1500 grams birth weight.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study involves two-arm parallel assignment where one group receives standard treatment (Ibuprofen) and the other group receives investigational medicinal product (Paracetamol) to treat Patent Ductus Arteriosus</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Infants will be randomized. Outcome assessor of the treatment will be blinded to the trial participants. No allocation concealment is done.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Conversion of haemodynamically significant PDA (hsPDA) to non-hsPDA</measure>
    <time_frame>3 days</time_frame>
    <description>Efficacy of Paracetamol (proposed new treatment) in treating hsPDA in comparison to Ibuprofen (current standard treatment) in preterm infants. The diagnosis of hsPDA will be made in the presence of supportive clinical signs and at least three of the following echocardiogram indices:&#xD;
i) PDA diameter ≥2.0 mm in 2D ii) Ductal flow pattern ('growing' pattern or pulsatile with Vmax/Vmin ≥ 2) iii) Retrograde post ductal aortic/coeliac/SMA (superior mesenteric artery) diastolic flow iv) LA/Ao ratio (left atrium:Aorta) ≥ 2 v) LVO (Left ventricular output) ≥ 300 ml/kg/min vi) Mitral valve E/A ratio ≥ 1&#xD;
An echocardiogram will be carried out within 72 hours of the last dose and PDA will be classified as non-hsPDA based on the following criteria - PDA closed OR any two of the following three parameters i) Reduction of PDA diameter &gt;50% (2D) ii) Restrictive or closing Ductal flow pattern iii) LA: Ao ratio &lt; 1.5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Broncho-pulmonary dysplasia (BPD) free survival at 36 weeks post menstrual age (PMA)</measure>
    <time_frame>Age up to 36 weeks PMA</time_frame>
    <description>BPD free survival at 36 weeks PMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications of prematurity in each group</measure>
    <time_frame>Age up to 36 weeks PMA</time_frame>
    <description>Necrotising enterocolitis (NEC, Bell stage ≥IIa)&#xD;
Significant intraventricular haemorrhage ( IVH) grade 3/4)&#xD;
Retinopathy of Prematurity (ROP) requiring treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To record any evidence of adverse effects with Paracetamol or Ibuprofen</measure>
    <time_frame>Within 7 days of starting the trial medications</time_frame>
    <description>. a) Renal impairment (elevated urea and creatinine &gt; upper limit of normal range) b) Hepatic impairment (elevated liver enzymes ALT or Aspartate transaminase (AST) &gt; upper limit of normal) c) Significant gastrointestinal or non-gastrointestinal bleeding requiring intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment arm which will provide the comparator arm to the proposed new treatment. This is routine standard of practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To study the efficacy of Paracetamol (proposed new treatment) in treating hsPDA in comparison to Ibuprofen (current standard treatment) in preterm infants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol injection</intervention_name>
    <description>Intravenous Paracetamol</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen injection</intervention_name>
    <description>Intravenous Ibuprofen</description>
    <arm_group_label>Ibuprofen</arm_group_label>
    <other_name>Brufen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age - &lt;32 weeks OR birth weight &lt; 1500 grams&#xD;
&#xD;
          -  Postnatal age ≤ 28 days&#xD;
&#xD;
          -  Meets criteria for hsPDA&#xD;
&#xD;
          -  Clinician's decision to treat PDA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for administration of Ibuprofen (cyclooxygenase-inhibitors) or&#xD;
             Paracetamol, such as: active bleeding (e.g. intracranial or gastrointestinal&#xD;
             haemorrhage), thrombocytopenia (&lt;50x109/L), renal failure (raised creatinine (&gt;100&#xD;
             micromole/l) or oliguria (&lt;0.5 mL/kg/hour), known or suspected necrotising&#xD;
             enterocolitis, any gastric or intestinal perforation, pre-treatment abnormal liver&#xD;
             function tests (ALT &gt; upper normal limit of the reference range, Bilirubin &gt; National&#xD;
             Institute of Clinical Excellence exchange phototherapy level).&#xD;
&#xD;
          -  Previous use of Ibuprofen or Paracetamol prior to randomisation.&#xD;
&#xD;
          -  Persistent pulmonary hypertension (ductal right-to-left shunt ≧33% of cardiac cycle).&#xD;
&#xD;
          -  Congenital heart defect, other than PDA or Patent Foramen Ovale (PFO).&#xD;
&#xD;
          -  Life-threatening congenital birth defects.&#xD;
&#xD;
          -  Chromosomal abnormalities and/or congenital anomalies associated with abnormal&#xD;
             neurodevelopment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arin Mukherjee, MRCPCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester University NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Dockery</last_name>
    <phone>0161 276 3863</phone>
    <phone_ext>63863</phone_ext>
    <email>karen.dockery@cmft.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Dockery</last_name>
      <phone_ext>63863</phone_ext>
      <email>karen.dockery@cmft.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 21, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT04986839/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT04986839/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

